Lightnews — Scholar-powered news

FirstWord Group

FirstWord Group

@firstwordgroup.com

210 followers 35 following 1.3K posts

FirstWord is a global leader in news and intelligence for the Pharma and MedTech industries. Find our services here www.firstwordpharma.com, www.firstwordhealthtech.com, and www.firstwordreports.com

Posts Media Videos Starter Packs

FirstWord Group @firstwordgroup.com · 1h

Alkermes builds out sleep portfolio with $2.1B Avadel takeout $ALKS $AVDL firstwordpharma.com/story/6376906

FirstWord Group @firstwordgroup.com · 1h

Electra nets $183M round to tame hyperinflammation with SIRP-targeted therapy firstwordpharma.com/story/6376904

FirstWord Group @firstwordgroup.com · 1h

Novartis touts steroid-sparing promise for Cosentyx in polymyalgia rheumatica $NVS firstwordpharma.com/story/6376838

FirstWord Group @firstwordgroup.com · 18h

Merck & Co. starts building Virginia site, part of $70B in planned US investments $MRK firstwordpharma.com/story/6328430

FirstWord Group @firstwordgroup.com · 20h

Neuphoria tanks after social anxiety drug flops in Phase III $NEUP firstwordpharma.com/story/6328411

FirstWord Group @firstwordgroup.com · 20h

Samsung Bioepis expands into ADCs after separating from CDMO unit firstwordpharma.com/story/6328071

FirstWord Group @firstwordgroup.com · 20h

AbbVie bolsters immunology hold as Rinvoq again edges out Humira $ABBV firstwordpharma.com/story/6328042

FirstWord Group @firstwordgroup.com · 1d

Neuralink rival CoMind raises $60M to bring brain monitoring to the ICU firstwordhealthtech.com/story/6326250

FirstWord Group @firstwordgroup.com · 1d

ctDNA-guided chemotherapy shows promise in colon cancer trial #ESMO25 firstwordpharma.com/story/6327548

FirstWord Group @firstwordgroup.com · 1d

Summit to push lung cancer hopeful ivonescimab toward FDA without OS win $SMMT firstwordpharma.com/story/6326363

FirstWord Group @firstwordgroup.com · 1d

IDEAYA's darovasertib impresses in twin ocular cancer trials $IDYA firstwordpharma.com/story/6327486

FirstWord Group @firstwordgroup.com · 1d

Exelixis shares fall as colorectal cancer drug hopeful shows mixed picture $EXEL #ESMO25 firstwordpharma.com/story/6326195

FirstWord Group @firstwordgroup.com · 2d

Novo Nordisk's oral GLP-1 Rybelsus gets FDA green light for heart protection $NVO firstwordpharma.com/story/6325224

FirstWord Group @firstwordgroup.com · 2d

Pluvicto slows progression of earlier-stage prostate cancer by 28% $NVS #ESMO25 firstwordpharma.com/story/6326042

FirstWord Group @firstwordgroup.com · 2d

Vivace preps Phase III move for Hippo-targeting mesothelioma drug #ESMO25 firstwordpharma.com/story/6326025

FirstWord Group @firstwordgroup.com · 2d

Bispecific ivonescimab beats PD-1 in China, setting stage for global test $SMMT $AKESF $MRK #ESMO25 firstwordpharma.com/story/6326043

FirstWord Group @firstwordgroup.com · 2d

Datroway, Trodelvy deliver parallel wins in metastatic TNBC $AZN $DSNKY $GILD #ESMO25 firstwordpharma.com/story/6325267

FirstWord Group @firstwordgroup.com · 3d

Padcev, Keytruda regimen given before, after surgery shines in bladder cancer $PFE $ALPMY $MRK #ESMO25 firstwordpharma.com/story/6324639

FirstWord Group @firstwordgroup.com · 3d

Detailed data from Enhertu's dual wins in early-stage, HER2+ breast cancer $AZN $DSNKY #ESMO25 firstwordpharma.com/story/6324606

FirstWord Group @firstwordgroup.com · 4d

Amgen, AstraZeneca's Tezspire snags rhinosinusitis FDA approval $AMGN $AZN firstwordpharma.com/story/6324607

FirstWord Group @firstwordgroup.com · 4d

Trump's promise to slash Ozempic cost sinks shares of obesity drugmakers $NVO $LLY firstwordpharma.com/story/6323875

FirstWord Group @firstwordgroup.com · 4d

Roche's Chugai inks $1.1B pact with Rani to move biologics beyond injections $RANI $RHHBY firstwordpharma.com/story/6323799

FirstWord Group @firstwordgroup.com · 4d

Imfinzi cuts death risk by 22% in early gastric cancer $AZN #ESMO25 firstwordpharma.com/story/6323652

FirstWord Group @firstwordgroup.com · 5d

TrumpRx welcomes Merck KgaA, one of nine to receive new priority voucher firstwordpharma.com/story/6323519

FirstWord Group @firstwordgroup.com · 5d

AstraZeneca expands Immunai collaboration to tackle inflammatory bowel disease $AZN firstwordpharma.com/story/6323272